Sun Pharmaceutical Industries' landmark $11.75 billion acquisition of US-based Organon & Co is set to strategically expand its portfolio into high-growth women's health and biosimilars segments, despite potential integration complexities and debt considerations. Photograph: Francis Mascarenhas/ReutersKey PointsSun Pharmaceutical Industries acquired US-based Organon & Co. for $11.75 billion, marking India's largest overseas pharma acquisition.The deal provides Sun Pharma entry into women's health and biosimi ...